Halozyme Therapeutics, Inc. reiterating its financial guidance for 2022, which was last provided on August 9, 2022 as a result of the close of the Antares Pharma transaction and strong year-to-date results. For the full year 2022, the Company expects: total revenue of $655 million to $685 million, representing growth of 48% to 55% over 2021 total revenue primarily driven by projected revenue contribution from the Antares business of $115 million to $125 million; GAAP operating income of $240 million to $265 million, which includes one-time transaction costs of approximately $45 million and amortization of approximately $80 million related to the Antares acquisition; GAAP net income of $170 million to $195 million; GAAP diluted earnings per share of $1.20 to $1.35 due to acquisition related costs in 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.92 USD | -3.43% | -3.24% | +18.83% |
05-22 | Halozyme Therapeutics Insider Sold Shares Worth $905,480, According to a Recent SEC Filing | MT |
05-07 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.83% | 5.79B | |
+10.79% | 115B | |
+11.65% | 106B | |
-6.20% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.41% | 17.56B | |
-40.50% | 17.32B | |
+6.64% | 14.03B | |
+31.84% | 12.13B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Halozyme Therapeutics, Inc. Reiterates Financial Guidance for the Year 2022